This synthetic peptide is derived from a protein found in the stomach, and it works throughout the body to repair tissues, improve gut health, and reduce inflammation
FDA has identified BPC-157 among substances considered in the context of bulk drug substances used in compounding, citing concerns that include potential immunogenicity risks, peptide-related impurities, and incomplete active-material characterizationunderscoring the need to avoid consumer-use, clinical-use, or self-administration interpretation
Liposomal encapsulation has real clinical support: a 2017 pilot trial in the European Journal of Clinical Nutrition found that liposomal glutathione at 500-1,000mg daily raised whole-blood GSH by 40%, PBMC glutathione by 100%, and NK cell cytotoxicity by up to 400% within two weeks faster and more pronounced changes than the reduced L-glutathione RCT showed (Sinha et al., 2017
Not Sure Which Peptide Protocol Fits Your Muscle Recovery Goal
Stabilized Butyric acid as soluble, pure, individual free fatty acid in a hexadextrin matrix molecular trap compounded with DexKey release agent (patent pending, Al Czap, Czap R&D, licensed by Tesseract Medical Research, LLC)
